Zhou et al. [20] recently found that SRSF1 is increased both in glioma tissues and cell lines, and its increased immunohistochemical expression is positively correlated with histological grade (from WHO grade II diffuse astrocytomas to WHO grade IV GBM), the Ki-67 index, and a predicted poorer prognosis in GBM patients. This evidence concerns the gene SRSF1 and glioblastoma.